BridgeBio Pharma (BBIO) said Wednesday it priced $500 million of 1.75% convertible senior notes due March 1, 2031 in a private offering, for about $489.5 million in expected net proceeds.
The company granted the initial purchasers an option to buy up to an additional $75 million of notes.
BridgeBio said it expects the offering to close Friday and plans to use a portion of the net proceeds to repay all outstanding borrowings under and terminate its January 2024 financing agreement, among other things.
The company's shares were down 5.2% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。